These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 18645005

  • 1. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [Abstract] [Full Text] [Related]

  • 2. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.
    Clin Cancer Res; 2008 Jul 01; 14(13):4175-85. PubMed ID: 18593997
    [Abstract] [Full Text] [Related]

  • 4. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
    Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C, Van Waes C.
    Clin Cancer Res; 2001 Feb 01; 7(2):435-42. PubMed ID: 11234901
    [Abstract] [Full Text] [Related]

  • 5. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct 01; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 6. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
    Fribley A, Zeng Q, Wang CY.
    Mol Cell Biol; 2004 Nov 01; 24(22):9695-704. PubMed ID: 15509775
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.
    J Clin Endocrinol Metab; 2006 Oct 01; 91(10):4013-21. PubMed ID: 16849420
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov 01; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr 01; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 13. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
    Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C.
    Int J Cancer; 2002 Jun 01; 99(4):538-48. PubMed ID: 11992543
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC.
    Clin Cancer Res; 2011 Aug 15; 17(16):5311-21. PubMed ID: 21724551
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.